Metronomic scheduling of a cyclic hexapeptide Ra-VII for anti-angiogenesis, tumor vessel maturation and anti-tumor activity

Cancer Science

Volumn 97, Issue 7, 2006, Pages 665-674

  Koizumi, Takayuki ^a   Abe, Mayumi ^a,c   Yamakuni, Tohru ^a   Ohizumi, Yasushi ^a   Hitotsuyanagi, Yukio ^b   Takeya, Koichi ^b   Sato, Yasufumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; HEXAPEPTIDE; PLANT EXTRACT; RUBIA EXTRACT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CORNEA CELL; CYTOKINESIS; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENDOTHELIUM CELL; GROWTH INHIBITION; IN VITRO STUDY; INHIBITION KINETICS; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; TUMOR VASCULARIZATION;

ANIMALS; BLOOD VESSELS; CARCINOMA, LEWIS LUNG; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC;

EID: 33745949179     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00229.x     Document Type: Article

References (17)

1. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
2. Falkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-11.
4. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
6. Folkman J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003; 2 (4 Suppl. 1): S127-33.
7. Brunton VG, MacPherson IR, Frame MC. Cell adhesion receptors, tyrosine kinases and actin modulators: A complex three-way circuitry. Biochim Biophys Acta 2004; 1692: 121-44.
8. Vicente-Manzanares M, Webb DJ, Horwitz AR. Cell migration at a glance. J Cell Sci 2005; 118: 4917-19.
9. Robinson DN, Swudich JA. Towards a molecular understanding of cytokinesis. Trends Cell Biol 2000; 10: 228-37.
10. Abe M, Inoue D, Matsunaga K et al. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells. J Cell Physiol 2002; 190: 109-16.
11. Itokawa H, Takeya K, Mori N, Hamanaka T, Sonobe T, Mihara K. Isolation and antitumor activity of cyclic hexapeptides isolated from Rubiae radix. Chem Pharm Bull 1984; 32: 284-90.
12. Fujiwara H, Saito S, Hitotsuyanagi Y, Takeya K, Ohizumi Y. RA-VII, a cyclic depsipeptide, changes the conformational structure of actin to cause G 2 arrest by the inhibition of cytokinesis. Cancer Lett 2004; 209: 223-9.
13. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988; 107: 1199-205.
14. Watanabe K, Hasegawa Y, Yamashita H et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004; 114: 898-907.
15. Kerbel R, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-36.
16. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
17. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.